WEE1 and Alzheimer disease: Protein kinase inhibitors constituted 26% of the antineoplastic and immunomodulating drugs suggested as AD repurposing candidates, followed by other antineoplastic agents (18%) and immunosuppressants (15%) (Figure 5B).